VRTX - Why Is Vertex Pharmaceuticals Stock Sliding Today? | Benzinga
Tuesday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced results from its Phase 3 program (two Phase 3 trials) for the selective NaV1.8 inhibitor, VX-548, for moderate-to-severe acute pain.
Treatment with VX-548 following abdominoplasty or bunionectomy surgery showed a statistically significant improvement in pain intensity difference from 0 to 48 hours (SPID48) compared to placebo and a clinically meaningful reduction in pain from baseline at 48 hours on the Numeric Pain Rating Scale (NPRS) in both studies.
Also Read: Vertex’s Non-Opioid Diabetes Associated Nerve Pain Treatment Candidate Aces Mid-Stage Trial.
For the first key secondary endpoint, Vertex tested the ...